Glecaprevir/pibrentasvir

Glecaprevir/pibrentasvir is a combination medication used in the treatment of Hepatitis C. It is a combination of two antiviral medications, glecaprevir and pibrentasvir. This medication is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin).

Mechanism of Action[edit | edit source]

Glecaprevir inhibits the HCV NS3/4A protease, which is necessary for the proteolytic cleavage of the HCV encoded polyprotein. Pibrentasvir inhibits the HCV NS5A protein, which is required for viral replication.

Indications[edit | edit source]

Glecaprevir/pibrentasvir is indicated for the treatment of adults with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.

Side Effects[edit | edit source]

Common side effects of glecaprevir/pibrentasvir include headache and fatigue. Serious side effects may include risk of hepatitis B virus reactivation in patients coinfected with HCV and HBV.

Drug Interactions[edit | edit source]

Glecaprevir/pibrentasvir can interact with other drugs and may alter their effectiveness or increase side effects. Some drugs should not be used together with glecaprevir/pibrentasvir.

Dosage[edit | edit source]

The recommended dosage of glecaprevir/pibrentasvir is three tablets (total daily dose: glecaprevir 300 mg/pibrentasvir 120 mg) taken orally once daily with food.

Precautions[edit | edit source]

Before taking glecaprevir/pibrentasvir, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems.

References[edit | edit source]

Glecaprevir/pibrentasvir Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.